Express News | Equillium Announces Q2 2024 Ending Cash, Cash Equivalents, And Short-Term Investments Total Approximately $33.3M, Up $1.0M From Q1; Increase Driven By $2.7M Australian Tax Credit For 2023 R&D Expenses

BenzingaJul 18 13:59 ET

Express News | Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

ReutersJul 18 13:57 ET

Equillium to Participate in Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)--$EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disord

BusinesswireJul 2 08:00 ET

Investors Don't See Light At End Of Equillium, Inc.'s (NASDAQ:EQ) Tunnel And Push Stock Down 54%

To the annoyance of some shareholders, Equillium, Inc. (NASDAQ:EQ) shares are down a considerable 54% in the last month, which continues a horrid run for the company. Longer-term shareholders will

Simply Wall StJun 16 08:59 ET

Equillium to Be Included in the Russell Microcap Index

LA JOLLA, Calif.--(BUSINESS WIRE)--$EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disord

BusinesswireJun 12 08:00 ET

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business WireJun 5 08:00 ET